Lyra Therapeutics Inc
NASDAQ:LYRA
Lyra Therapeutics Inc
NASDAQ:LYRA
Price:
0.3558 USD
-4.35%
Updated:
May 16, 2024
Lyra Therapeutics Inc
Selling, General & Administrative
|
Lyra Therapeutics Inc
Selling, General & Administrative Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Selling, General & Administrative
-$19.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$21.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.5B
|
CAGR 3-Years
-76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$7.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
See Also
What is Lyra Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-19.1m
USD
-19.1m
USD
Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Selling, General & Administrative amounts to -19.1m USD.
What is Lyra Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-40%
-40%
Over the last year, the Selling, General & Administrative growth was -9%. The average annual Selling, General & Administrative growth rates for Lyra Therapeutics Inc have been -25% over the past three years , -40% over the past five years .
You don't have any saved screeners yet
